Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Rating) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,897 shares of the medical equipment provider’s stock after purchasing an additional 637 shares during the period. Intuitive Surgical comprises 0.3% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 27th biggest position. Simplify Asset Management Inc.’s holdings in Intuitive Surgical were worth $2,095,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Creative Planning boosted its stake in shares of Intuitive Surgical by 11.8% in the fourth quarter. Creative Planning now owns 43,607 shares of the medical equipment provider’s stock worth $11,571,000 after acquiring an additional 4,603 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Intuitive Surgical by 1.3% in the fourth quarter. First Horizon Advisors Inc. now owns 5,839 shares of the medical equipment provider’s stock worth $1,549,000 after buying an additional 75 shares in the last quarter. PAX Financial Group LLC lifted its stake in shares of Intuitive Surgical by 39.5% in the fourth quarter. PAX Financial Group LLC now owns 4,921 shares of the medical equipment provider’s stock worth $1,306,000 after buying an additional 1,394 shares in the last quarter. Bryn Mawr Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at approximately $382,000. Finally, Zions Bancorporation N.A. increased its holdings in shares of Intuitive Surgical by 4.2% in the fourth quarter. Zions Bancorporation N.A. now owns 9,661 shares of the medical equipment provider’s stock valued at $2,564,000 after purchasing an additional 393 shares during the last quarter. Hedge funds and other institutional investors own 81.96% of the company’s stock.

Insider Buying and Selling

In related news, Director Mark J. Rubash sold 7,323 shares of Intuitive Surgical stock in a transaction that occurred on Friday, April 28th. The stock was sold at an average price of $300.00, for a total value of $2,196,900.00. Following the sale, the director now directly owns 15,482 shares in the company, valued at $4,644,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Intuitive Surgical news, Director Mark J. Rubash sold 7,323 shares of the stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $300.00, for a total value of $2,196,900.00. Following the completion of the transaction, the director now directly owns 15,482 shares of the company’s stock, valued at $4,644,600. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Myriam Curet sold 1,253 shares of the company’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $228.47, for a total value of $286,272.91. Following the completion of the sale, the executive vice president now directly owns 1,950 shares in the company, valued at approximately $445,516.50. The disclosure for this sale can be found here. Insiders sold 61,276 shares of company stock valued at $18,253,410 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the topic of a number of analyst reports. Raymond James lifted their target price on shares of Intuitive Surgical from $270.00 to $323.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 19th. UBS Group assumed coverage on Intuitive Surgical in a research note on Tuesday, March 28th. They set a “neutral” rating and a $278.00 target price for the company. Piper Sandler raised their target price on Intuitive Surgical from $265.00 to $315.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 19th. StockNews.com initiated coverage on shares of Intuitive Surgical in a research note on Thursday, May 18th. They set a “buy” rating for the company. Finally, Bank of America increased their target price on shares of Intuitive Surgical from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, April 19th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $300.50.

Intuitive Surgical Trading Up 0.8 %

Shares of Intuitive Surgical stock traded up $2.50 on Friday, hitting $306.27. The stock had a trading volume of 479,983 shares, compared to its average volume of 1,665,196. Intuitive Surgical, Inc. has a 52-week low of $180.07 and a 52-week high of $317.81. The stock has a market cap of $107.32 billion, a price-to-earnings ratio of 83.00, a P/E/G ratio of 5.41 and a beta of 1.31. The company’s 50 day moving average price is $280.97 and its 200 day moving average price is $263.32.

Intuitive Surgical (NASDAQ:ISRG – Get Rating) last announced its earnings results on Tuesday, April 18th. The medical equipment provider reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Intuitive Surgical had a net margin of 20.40% and a return on equity of 11.39%. The business had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.59 billion. During the same period in the previous year, the company posted $1.00 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. Analysts predict that Intuitive Surgical, Inc. will post 4.3 EPS for the current fiscal year.

About Intuitive Surgical

(Get Rating)

Intuitive Surgical, Inc engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G.